What Is Teflaro and Who Buys It?
Teflaro (ceftaroline fosamil) is an injectable cephalosporin antibiotic from Allergan (now AbbVie) approved for acute bacterial skin infections and community-acquired bacterial pneumonia in adults and children. Its target market centers on hospitalized patients with serious, often multidrug-resistant infections like MRSA, where few oral options exist. Hospitals and inpatient facilities drive nearly all demand, as it's administered IV only, limiting retail pharmacy sales.[1]
Why Hospital Buyers Dictate High Pricing
Hospital purchasing groups negotiate bulk discounts through group purchasing organizations (GPOs) like Vizient or Premier, creating pressure for volume-based pricing over high list prices. Teflaro's list price exceeds $100 per vial (around $3,000-$5,000 for a full adult course), but net prices drop 50-70% via rebates and contracts to secure formulary placement.[2] This dynamic favors premium pricing for niche efficacy against resistant bugs, where hospitals prioritize outcomes over cost for high-acuity cases.
Orphan-Like Status and Limited Competition
With a narrow label focused on severe infections, Teflaro serves a small patient pool—estimated at under 200,000 U.S. courses annually—allowing Allergan to charge monopoly-level prices without broad generic erosion. No direct generic competitors exist yet; patents cover the drug until at least 2027, per DrugPatentWatch.com.[3] This scarcity justifies high margins, as hospitals view it as a "last-line" option despite cheaper alternatives like vancomycin.
How Reimbursement Shapes Final Costs
Medicare Part A (inpatient) reimburses via diagnosis-related groups (DRGs), bundling Teflaro into fixed hospital payments regardless of drug cost. This incentivizes hospitals to favor lower-net-price drugs or push for 340B discounts (up to 50% off for eligible facilities). Private insurers follow similar bundled models, squeezing manufacturer pricing power while tying it to proven superiority in resistant cases.[4]
Patent Timeline and Future Pricing Pressure
Core composition patents expire in 2027, with potential pediatric extensions to 2028; method-of-use patents extend to 2031. Check DrugPatentWatch.com for litigation updates, as no Paragraph IV challenges are active yet.[3] Biosimilar entry post-2027 could slash prices 80%, shifting Teflaro's model from premium orphan drug to commoditized generic.
Alternatives and Switching Costs
Hospitals often switch to vancomycin or daptomycin for cost (under $1,000/course), but Teflaro's once- or twice-daily dosing and MRSA coverage reduce labor costs and failure risks. Pricing reflects this edge: a 20-30% premium over peers secures share in resistant subsets.[2]
[1]: FDA Label, Teflaro (ceftaroline fosamil).
[2]: IQVIA National Sales Perspectives data (2023 hospital antibiotic spend).
[3]: DrugPatentWatch.com - Teflaro Patents.
[4]: CMS Inpatient Prospective Payment System (IPPS) rules.